Breast cancer screening tool predicts patient response to immunotherapies

UNC Lineberger awarded up to $28M from ARPA-H to develop clinical trial for metastatic breast cancer

UNC Lineberger Comprehensive Cancer Center has been awarded up to $28 million by the Advanced Research Projects Agency for Health to lead the development of a next-generation clinical trial for breast cancer that has spread to other parts of the body.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Drugs & Targets

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.

June 06, 2025

Vol.51 No.22

Drugs & Targets

China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer

The National Medical Products Administration in China approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

June 06, 2025

Vol.51 No.22

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.

May 30, 2025

Vol.51 No.21

By Claire Marie Porter

Breast cancer screening tool predicts patient response to immunotherapies

YOU MAY BE INTERESTED IN

UNC Lineberger awarded up to $28M from ARPA-H to develop clinical trial for metastatic breast cancer

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Renew today!

Subscriber content

Never miss an issue!

Login

Breast cancer screening tool predicts patient response to immunotherapies

YOU MAY BE INTERESTED IN

UNC Lineberger awarded up to $28M from ARPA-H to develop clinical trial for metastatic breast cancer

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan AfricaWith help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Never miss an issue!

Login

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries